Key result
Acute coronary syndrome increased mean Lp(a) at 7-14 days, 1 month, and 3-6 months vs baseline.
Why the study?
Although Lp(a) is generally considered stable over a lifetime, ACS may transiently alter Lp(a) concentrations and complicate interpretation, prompting a systematic evaluation of temporal changes following ACS.
Does acute coronary syndrome transiently alter Lipoprotein(a) concentrations over subsequent weeks to months compared to initial post-ACS measurements?
Meta-Analysis (n=1,396)
Yes
Does acute coronary syndrome transiently alter Lipoprotein(a) concentrations over subsequent weeks to months compared to initial post-ACS measurements?
Answers are grounded in this paper and cite their sources.
Early post-ACS Lp(a) measurements may underestimate long-term concentrations by 22% to 44%, warranting repeat testing weeks to months later when values are near clinical decision or therapy eligibility thresholds.
AIMS: Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor generally considered stable over an individual's lifetime. Acute coronary syndrome (ACS) may transiently alter Lp(a) concentrations, complicating interpretation. We systematically evaluated temporal changes in Lp(a) following ACS. METHODS: This PRISMA 2020-guided systematic review searched MEDLINE and Embase from database inception to February 2026. Eligible studies reported serial Lp(a) measurements at two or more time points after index ACS event. Exploratory random-effects meta-analysis of percent change in mean Lp(a) was performed. RESULTS: Of 3,811 records, 16 studies comprising 1,396 patients met inclusion criteria. Lp(a) demonstrated a dynamic post-ACS trajectory. Using initial post-ACS measurements as the reference, pooled percent change in mean Lp(a) was non-significant at 24 hours post-ACS (+2.5%, 95% CI -6.8 to 11.7; p=0.602). Lp(a) was significantly higher at 7-14 days (+44.0%, 95% CI 4.0-84.1; p=0.031), 1 month (+28.3%, 95% CI 2.7-54.0; p=0.030), and 3-6 months (+22.2%, 95% CI 2.4-42.0; p=0.028). Across two studies, absolute Lp(a) increases >25 nmol/L occurred in 17% and 22% of patients by 3 and 6 months, respectively. CONCLUSIONS: Lp(a) is not static post-ACS. Early post-ACS measurements may underestimate long-term concentrations and risk. Repeat measurement weeks to months later is most informative when initial post-ACS Lp(a) values are near clinical decision thresholds or would influence eligibility for emerging Lp(a)-lowering therapies.
No takes yet. Share an insight, caveat, or question.
Shokravi et al. (2026) conducted a meta-analysis in Acute coronary syndrome (ACS) (n=1,396). Serial Lipoprotein(a) [Lp(a)] measurement following acute coronary syndrome vs. Initial post-ACS Lp(a) measurement (baseline reference) was evaluated on Pooled percent change in mean Lipoprotein(a) [Lp(a)] from initial post-ACS measurement (+44.0% at 7-14 days; +28.3% at 1 month; +22.2% at 3-6 months, 95% CI 4.0-84.1 (at 7-14 days), p=0.031 (at 7-14 days)). Acute coronary syndrome increased mean Lp(a) at 7-14 days, 1 month, and 3-6 months vs baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: